Business
Inspira™ Announces Start of Production of the INSPIRA™ ART100
RA'ANANA, Israel, May 2, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), a breakthrough medical
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"RA'ANANA, Israel, May 2, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the \"Company\" or \"Inspira\"), a breakthrough medical technology company, announced the start of production of the INSPIRA ART100 medical device.\n\nThe INSPIRA ART100 device is being contract manufactured by a leading technology company that provides high-technology electronic assembly solutions for the medical, aero-space and aviation, communications and defense industries. The manufacturer has commenced with the production and assembly of the first batch of INSPIRA ART100 devices, which will be used for deployment in several initial sites, subject to U.S. Food and Drug Administration (FDA) regulatory clearance.\nAbout Inspira Technologies OXY B.H.N. Ltd. \nInspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.\nFor more information, please visit our corporate website: https://inspira-technologies.com\nForward-Looking Statement Disclaimer \nThis press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the planned deployment of its INSPIRA ART100 and its regulatory path. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as other...